抗体医薬の展望 高 ADCC 活性型抗体を中心に
17 抗体医薬の展望 高ADCC 活性型抗体を中心に 設楽 研也 協和発酵工業(株)東京研究所 042-725-2555、kshitara@kyowa.co.jp 1. はじめに 現在、米国では10種類を超える抗体が医薬品として販売されており …
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され, 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Since 1874 遺伝子治療用製品の開発における 国内 …
www.nihs.go.jp遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
Guidelines, Studies, Solid, Dosage, Guideline for bioequivalence studies for, Bioequivalence, Solid dosage
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
Pharmaceutical, Clinical, Studies, Clinical pharmacokinetic studies of pharmaceuticals, Pharmacokinetic
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名: n-(2-
毒物及び劇物取締法Q&A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q&A 質問一覧 1.毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
Management, European, Quality, Risks, Agency, Quality risk management, Medicine, European medicines agency, Nihs, Ich q9
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Management, Quality, Risks, Nihs, Ich q9 quality risk management nihs, Ich q9 quality risk management
Related documents
REFERENTIEL REGIONAL ONCO-LR Comité Onco-Hématologie
www.oncolr.orgPage 1 REFERENTIEL REGIONAL ONCO-LR Comité Onco-Hématologie Leucemie Lymphoïde Chronique B Groupe de travail: Dr Burcheri, Dr Donadio, Dr Garrido, Dr Legouffe, Dr Quinquenet, Dr Quittet, Dr Rolland, Dr Saad, Dr Vergely, Dr Waultier, Pr Cartron
Liste des collaborateurs par Sénateur - senat.fr
www.senat.frListe des collaborateurs par Sénateur A.G.A.S. Employeur Nom usuel1 Mme CARRÈRE Maryse M. BEGUE Julien M. OCTOR Dennis Mme CARTRON Françoise M. CHARLON Fabien
CARTE AUTOMNE-HIVER 2018 - courtepaille.com
www.courtepaille.comÀ ou pas ! partager... Les spécialités du Grillardin, cuites devant vous, et toujours avec goût ! Et pour encore plus de saveurs, demandez
Carnet d’adresses de la - Sauvegarde 56
www.sauvegarde56.orgSauvegarde 56 Secrétariat de Direction Générale 33 cours de Chazelles BP 20347 56103 LORIENT Cedex Tél. : 02.97.36.19.70 Fax. : 02.97.85.08.90